Jupiter Neurosciences (JUNS) Total Non-Current Liabilities (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Total Non-Current Liabilities of $1.8 million for Q1 2025, up 2929.93% year-over-year from $59873.5 in Q1 2024, and down 65.31% quarter-over-quarter from $5.2 million in Q3 2024.
Jupiter Neurosciences (JUNS) Total Non-Current Liabilities (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Total Non-Current Liabilities for 3 consecutive years, with $1.8 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Total Non-Current Liabilities rose 2929.93% year-over-year to $1.8 million; the TTM figure through Mar 2025 stood at $1.8 million (up 2929.93% YoY), while the FY2023 annual figure was $4.4 million, changed N/A from the prior year.
- Total Non-Current Liabilities eased to $1.8 million in Q1 2025 per JUNS's latest filing, from $5.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.2 million in Q3 2024 and bottomed at -$64105.0 in Q1 2024.
- Historically, Total Non-Current Liabilities has averaged $2.9 million across 3 years, with a median of $3.1 million in 2023.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 2929.93% in 2025 and fell as far as 2929.93% in 2025.
- Jupiter Neurosciences' Total Non-Current Liabilities stood at $4.4 million in 2023, then advanced by 17.67% to $5.2 million in 2024, then slumped by 65.31% to $1.8 million in 2025.
- Business Quant data shows JUNS's Total Non-Current Liabilities at $1.8 million in Q1 2025, $5.2 million in Q3 2024, and -$64105.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.81 Mn |
| Sep 30, 2024 | 5.23 Mn |
| Mar 31, 2024 | -64,105.00 |
| Dec 31, 2023 | 4.44 Mn |